多発性骨髄腫治療の再考:免疫ベースの併用療法を導く生物学的および臨床的洞察
Annamaria Gullà1, Madhav V Dhodapkar2, Hermann Einsele3
1Candiolo Cancer Institute , Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.
Abstract:
The standard of care for multiple myeloma has rapidly evolved to include immune-based therapies. However, achieving durable immune control and long-term survival, particularly in high-risk patients, remains difficult. In this article, we review the immune effects of existing and emerging therapies, dissect key drivers of resistance, highlight rational combinations and treatment-sequencing strategies, and summarize ongoing clinical trials that aim to optimize durable immune control. We discuss how the application of these biological and clinical insights may help us rethink multiple myeloma treatment to fully eradicate residual disease and elicit sustained natural and/or synthetic tumor-specific immunity.
Significance:
Preclinical and clinical insights are reshaping how immune-based therapies are used in multiple myeloma. This review explores how optimizing the integration of natural and synthetic immunity can support a shift from disease control to deep, durable immune eradication, paving the way for personalized immune strategies tailored to individual immune profiles.
関連する概念動画
Introduction to Biological Bases of Psychology
The nervous system, the cornerstone of...
What is Conservation Biology?
What is the Immune System?
Multiple Allele Traits
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Biological Effects of Radiation


